Good day and welcome to The Beauty Health Company Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Eduardo Rodriguez, Senior Director of M&A and Investor Relations. Please go ahead.

Thank you, operator and good morning, everyone. Thank you for joining The Beauty Health Company's conference call to discuss our second quarter 2023 financial results, which were released this morning and can be found on our website at beautyhealth.com. We encourage you to join the webcast accessible on our website, which contains a presentation that will be referenced during this call. With me today are Beauty Health's President and Chief Executive Officer, Andrew Stanleick; Incoming Chief Financial Officer, Michael Monahan and Chief Operating Officer, Brad Hauser Before we begin, I would like to remind you of the company's safe harbor language. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. Listeners are cautioned not to place undue reliance on any forward-looking statements. For a further discussion of risks related to our business, see our filings with the SEC. This call will present non-GAAP financial measures. Reconciliation of these non-GAAP measures to the most comparable GAAP measures are in the earnings release furnished to the SEC and available on our website. I will now turn the call over to Andrew.

Thank you, Eduardo, and thank you, everyone, for joining us. Today's call is going to be organized a bit different than usual. First, we'll review the highlights of our Q2 results before turning to some key learnings and actions taken through this period of rapid growth. I will then walk you through our 2023 outlook, and we will conclude with a preview of our innovation pipeline from Chief Operating Officer, Brad Hauser. We expect you saw the press release this morning announcing Michael Monahan as our new CFO. This is a critical role, and I am confident that Mike brings the right expertise that we need for this next phase of growth. I am tasking Mike with enhancing our financial strategy, planning, and reporting capabilities. To that end, I do want to thank Lian for her leadership during a formative period for Beauty Health. She helped manage the company through a period of transformational growth, including navigating through the pandemic. We are grateful for her contribution and wish her well. Mike will assume the role of CFO effective tomorrow. Lian will stay on as an advisor until September 01 to ensure a smooth transition. I will now hand off to Mike for a brief introduction.

Thanks, Andrew. I'm happy to be here today, and I look forward to meeting and building relationships with you all over time. My decision to join Beauty Health is based largely on the incredible growth opportunity ahead. Beauty Health is an impressive company with solid business fundamentals that I believe has a lot of room for profitable growth. As Andrew mentioned, my first day is tomorrow. I plan to use my first 90 days to immerse myself in the business, working to fully understand our financial controls, planning, and reporting. I look forward to sharing my impressions with you all in due course. I will now turn the call back to Andrew.

Thank you, Mike. We are happy to have you on board. I want to start by thanking the Beauty Health team around the world for their hard work in the second quarter and ongoing contributions as we focus on driving long-term shareholder value. Now for the second quarter results; there are five key takeaways from the quarter as we recommitted to our core business. First, we delivered net sales of $117.5 million and adjusted EBITDA of $17.8 million on continued demand for HydraFacial. These results represent net sales growth of 13% and adjusted EBITDA growth of 22%. As a reminder, this quarter we are comparing against the US launch of Syndeo last year, the company's single biggest product launch to date, where we benefited from $23.3 million of trade-up demand. When excluding the impact of trade-ups, our total year-over-year net sales growth for Q2 2023 was 32%. The second takeaway is consumer engagement, where our brand continues to grow. We see this in strong consumables net sales, which were $51.9 million, up 34% year-over-year on increased volumes. Third, as anticipated, we saw continued strength in EMEA and APAC. In China, we achieved year-over-year net sales growth of 265% or 167% when excluding trade-ups. We continue to see re-acceleration in China and remain enthusiastic about the growth potential of this market. The fourth takeaway, we generated adjusted EBITDA of $17.8 million at a margin of 15.1%, owing to 7.1% of adjusted operating expense leverage, compared to last year. However, those leverage gains were largely offset by 6.1% of adjusted gross margin headwinds, partially caused by Syndeo US launch-related impacts, which Liyuan will discuss in a moment. And the final takeaway for the quarter, based on the continued demand for HydraFacial, the re-acceleration in China and our ability to drive operating leverage,…

Thank you, Andrew, and thank you to everyone joining the call. Today I will walk you through our second quarter results, cost and balance sheet highlights, then hand back to Andrew to walk you through our outlook for 2023. Turning to net sales detail on Slide 10, we delivered total net sales of $117.5 million in the second quarter, up 13% year-over-year. This quarter, we are comparing against last year's US launch of Syndeo, which benefited from $23.3 million of trade-up demand. When excluding trade-ups, our total net sales growth for the quarter was 32%. In total, delivery system net sales were $65.6 million, roughly flat versus last year. When excluding trade-ups, delivery system net sales grew 30% year-over-year, on volume growth of 56%. As expected, our trade-up volumes declined 64% and contributed $11.6 million to net sales. We continue to expect total trade-up net sales in 2023 to exceed the $23.3 million of trade-up demand seen in Q2 of last year. We ended the quarter with a global install base of 29,682 and sold 2,822 delivery systems at an average selling price of $22.9 million, a slight decline from last year. This was driven by a few factors. First, a mixed shift in the Americas towards older generation of refurbished devices, amidst tightening credit for providers and a degree of holdback from US providers anticipating Syndeo enhancements to improve the user experience. Second, reduced elite pricing internationally following Syndeo's launch in our direct international market. Moving to consumables, strong growth in volume across the globe, drove net sales growth of 34% to $51.9 million and finally, breaking down our performance by region. In the Americas, we generated total net sales of $63.6 million, a decline of 16% when compared against last year. As expected, this was driven by fewer…

Thank you, Liyuan. On Slide 15, we share our expectations for the second half of 2023. We reaffirm our 2023 guidance, driving to projected net sales of $460 million to $480 million and refine our adjusted EBITDA margin target to a more precise 18% to 19% range. We acknowledge that due to pandemic impacts, a new product launch and relative newness as a public company, modelling our growth has not been straightforward. As a result, we are providing incremental colour to provide clarity on our expectations for the third quarter. We expect this incremental colour to be temporary and unnecessary to continue once we lap these dynamics early next year. Consistent with traditional seasonality in the medical aesthetics industry, we expect Q3 net sales to be in line to a slight step down from Q2 net sales figures, or a range of $110 million to $120 million. We expect Q3 adjusted EBITDA margin to step up slightly from Q2 to a range of 18% to 20%, driven by minor sequential improvement in adjusted gross margin versus Q2, increased selling and marketing leverage as marketing investments seasonally recede in the back half of the year, and tight cost discipline with G&A. Q4 is historically the largest quarter for the medical aesthetics industry and ours is no different. With Syndeo's enhancements expected to be largely completed, resurgence in China as it comps the 2022 pandemic lockdowns, and continued volume growth in consumables, we remain confident in our ability to land within our guided fiscal 2023 range. Our confidence is bolstered by the fundamentals of our business, which we spoke about earlier, and the favourable market dynamics that we anticipate will continue to drive our business. With every system we place, we unlock a long-term sustaining revenue stream. For those of you unfamiliar…

Thank you, Andrew. It's a pleasure to be here today. I have been in the aesthetic space for many years, and I'm proud to have worked with many of the industry's most successful devices and brands. I must say, I have rarely been as excited about an innovation pipeline as I am about the opportunity in front of Beauty Health. Since joining in January, I've taken on end-to-end product oversight from innovation to production to go to market. My goal has been to focus the organization on innovations that will deliver long-term sustained profitable growth. First, Syndeo. You all know it as our next generation connected device to deliver powerful insights and efficiencies for our providers. What we're unlocking next is Syndeo's one-stop plug-and-play platform capabilities. We envision a future where Syndeo becomes a revenue-generating Swiss Army knife, serving as the centerpiece of the treatment room. Today, we plug-and-play our LED shield from LightStim. You can imagine in the future where we can power a dermatoscope or other skin assessment tools to give the STs an in-room diagnostic, or even a laser or oxygen facial handpiece. With this, our providers can offer complementary treatments all in one device. We intend to add a new handpiece with complementary functionality to Syndeo every 12 to 18 months. And as Syndeo is the flagship device in our line-up, our new connected Allegro serves as the entry-level offering. The upgraded Allegro provides the same trademark HydraFacial glow, but without many of the defining features of Syndeo. The entry-level pricing offers flexibility for us to attract even more providers, particularly newly graduated estheticians just beginning their careers. Boosters are already central to the HydraFacial approach to personalization and co-created R&D with a number of strong partners. You will continue to see us launch marquee booster…

Thank you, Brad. Indeed, we have never had a stronger innovation pipeline and this will provide us with long-term, sustainable, multi-dimensional growth opportunities and we look forward to sharing more updates at a Beauty Health Investor Day in H1 of 2024. Operator, we're now ready to take any questions.

[Operator instructions] The first question comes from Oliver Chen with TD Cowen. Please go ahead.

Hi. Thank you very much. Would love your thoughts on the teething issues and what that implies in terms of timing and how much impact that is having across the Syndeos, as well as you thought about guidance, you mentioned some of those issues caused gross margin headwinds. How are you able to reaffirm the margin guidance in the context of that and a follow-up on China. Just we're seeing some optimism, but some caution in China. Would love your reads on how that's interplaying with the traffic and what you're seeing. Thanks very much.

Good morning, Oliver. Thanks for the questions. So I'll start with the Syndeo issue. So as you know, our vision for Syndeo is that it's a connected platform, and that Swiss army knife at the center of the provider's treatment room and when we launched it, it was a real leap forward. But I think, as we've talked before, with any high-tech IoT product, especially those first out of the gate, like the ones in the US, there was an element of iterative improvement once it's in the real world. So in part, part of the teething issues were software-related and part of the issue was user experience and hardware. And I think, as providers put Syndeo to work over the course of last year, particularly in the US, going through hundreds of treatments, we observed opportunities to improve the customer experience and overall performance and reliability. So we pushed through new software updates, which very specifically was related to forcing a rinse cycle, etcetera, because we were finding that some of the first generations had some residue buildup and blockage and other ones were simply simple component upgrades. This has mainly been a US teething issue, because over the course of last year, we've talked about it on previous calls, we were able to make those amendments ahead of the international launch. So we've been putting the customer first and obviously invested, as we've spoken before, about replacing every machine if a customer called in with a problem, we're very fast to take the machine back and switch it out. But of course, that cost us money, which was unplanned, but we felt that we must put the customer first. They're with us for the long term, and that pays off, and they appreciate that support. So we're putting…

The next question comes from Korinne Wolfmeyer with Piper Sandler. Please go ahead.

Hey, good morning, team. Thanks for taking the question. So I just like to touch on the guidance and really appreciate the color you gave kind of on more of like the quarterly cadence and what to expect for Q3 and Q4. But it does kind of lead into a pretty strong ramp in EBITDA margin in Q4, can you just talk about, one, what gives you confidence that we'll see that big lift step up in Q4? And then, two, where is that really going to come from? If you're still going to see some added gross margin pressure, is it really going to come from the marketing expense and SG&A? Kind of where are we going to see that leverage pull through? Thank you.

Korinne, thank you for the question and I'm glad you asked it because I think it's important that we walk through this together on the call. We maintain our conviction and our ability to hit our guidance in the back half. We started this year mentioning this was going to be a back half-weighted year, and that has not changed. I think as China recovers, we expect continued growth in the region. You recall in Q3, and especially in Q4 last year, China was locked out. So we had no business. That's bounced back strongly, as has EMEA. And as you know, we've spoken before about the higher contribution margins for those international businesses, especially in Asia. So that contributes. Also, we are still in launch phase, dropping a lot of new systems globally and in the back half of the year, we placed 30% growth on new systems globally in Q2. That will continue as we roll out Syndeo internationally in the second half, as we count that. Thirdly, we've got, of course, exciting booster portfolio launches coming in the second half, including some local in Q4 Asian boosters, which Brad talked about in China. Moreover, we're getting, as we experienced already this quarter, degrees of operating leverage throughout the P&L, beyond the fixed cost leverage you'd expect to see with our revenue growth. So in addition, as you mentioned, we expect to see receding OpEx investments, our marketing and advertising is very front half-weighted because of all the trade shows in our industry where we generate the leads, and that typically recedes. So we have line of sight to the back half and I personally went through the details of this financials for the back half of the year. Given the CFO transition, I feel confident in our ability to use various levers to achieve our guidance.

The next question comes from Margaret Kaczor with William Blair. Please go ahead.

Hey, good morning. Thanks for taking the questions. I'm going to take a second crack at the guidance comment, both on the top line and the bottom line and you touched on it a little bit, Andrew, there, but maybe if we go into specifics. So if we look at the historical, I guess, Q4 trends pre-COVID, those look like, to me at least, that they were up kind of in the mid-20s sequentially from Q3 to Q4, more recently in COVID, I guess, impacted years, it was in the teens. The number you provided today looks like it's closer maybe to the high 20s from Q3 to Q4. So again, is that more China? Is it something else? Are my numbers wrong? Maybe they are. And then as you think about adjusted EBITDA, does that EBITDA, I guess, rely on revenues kind of hitting the number that you've got? Thank you.

Margaret, thank you. Great questions, important. So a few things as we unpack that. First of all, looking back at the historical years you referenced, remember, recall back there, China was very nascent back then. We didn't have teams on the ground in Shanghai, Beijing, Shenzhen, which we have now, as was EMEA. Now, of course, we've made all those investments during the last two or three years, which are really bearing fruit. So when you add on those building blocks with the expansion of our business, the Syndeo launch, the new consumables, that's how we bridge that. In terms of EBITDA, you were very confident in our ability to deliver the EBITDA with the momentum we have, with the leverage we're getting. We'll also see some gradual sequential improvement in gross margin in the back half of the year, and that's why we have confidence and line of sight to deliver the guidance provided.

The next question comes from Jon Block with Stifel. Please go ahead.

Thanks, guys. Maybe the first question, the year ago EBITDA figures have changed yet again. So I see in the PR, the 1H '23 EBITDA is now $18.3 million. It was $13.8 million. So, it was revised higher by 30%. The 1H '23 EBITDA margin arguably benefits by about 250 bps. And just from some of the footnotes, it seems like more add-backs were baked into the year ago numbers so that it's apples to apples with the 1H '23 add-backs. So I guess, one, do I have that right? And then, Liyuan, how much does the 2023 EBITDA margin of 18% to 19% benefit from these incremental add-backs relative to your original guidance when you gave that, whatever that was, six months ago? The follow-up, Andrew, the '23 revenue is unchanged. The gross margins are arguably lower. So some of the EBITDA is being made up, within OpEx, likely sales and marketing when you look at the adjusted numbers. Maybe just your comfort that you're not sacrificing, call it investments in sales and marketing in '23 in order to hit the near-term margin targets, which might be, creeping more longer-term growth or trajectory of longer-term growth in '24 and beyond. Thanks, guys.

Jon, thank you. I'll take those. I'll start with your last question and then work back. First of all, just to reaffirm, we have, and I have personally total confidence in our guidance in the year to go. On the way we're investing, we're learning all the time in terms of our sales and marketing. We've been operating in marketing spent sort of in that 10% to 12% of sales, and that's, of course, increased year-on-year value as we've grown bigger. And, our spend is typically front-weighted, but we've really shifted and learned about how we invest, be it from the global illusion, which we've highlighted on the call, the way we're investing in broader reach digital, which both the provider to drive conversion of new systems and consumers are actually being a lot more efficient in how we invest in our marketing dollars, and we're seeing that in the ROIs we track. So I must say we're feeling, very confident that we're not in any way reducing our funds there. We're just getting leverage from efficiencies in terms of OpEx and our structures, which are bearing fruit. You saw that operating leverage come through this year already in Q2. In terms of your, going back in terms of your adjustments. So, yes, in H2 of last year, we didn't put our bonus for our teams in the H2. We also, to be apples to apples, removed it this year because so much of our comp is either base salary or equity. Indeed, we paid equity as a bonus to our teams this year. So we're very aligned with the shareholders. So we've taken that out of H2, so it's apples for apples. So that explains that adjustment since including in the footnotes.

The next question comes from Navann Ty with BNP. Please go ahead.

Hi, good morning. Thanks for taking my question. Can you spend more time on the US credit tightening conditions? So is that Med Spa? Med Spa struggling to find the body financing and did Beauty Health markets refurbish systems at all? I'm also interested to know about the immediate priorities of Michael Monahan from his appointment tomorrow. Thank you.

Thank you, Navann. You're a little bit difficult to hear, but first of all, I'll address your first one. I think you were talking about the health of the market and general credit. I think first of all, you mentioned the medical spa. The medical spa both in the US and globally is very, very buoyant. As you know, it's over 60% of our business and the most productive, and its growing fast and continues. I think what I refer to in terms of the pressure on our gross margin related to systems actually is less so from the chain. They've continued to invest, and that's why even the US, you saw that really strong growth in systems of 20% in Q2, and that's comping last year's Syndeo launch with new systems, new doors, increasing penetration and market share. I think where we've seen the pressure is those estheticians who are just out of school; they would be just buying their first device and I think what they've been telling us with higher interest rates, financing now is they're getting quotes up to nearly 20% on financing and that, if you're looking at Syndeo, which is a recommended price of circa $40,000, that's a big ask for them to take on. I think that's why they've been seeking either refurbished Syndeo systems or the Allegro system, which is a perfect price point for them, around $20,000. So we've been able to serve them. In saying that, we walked away from over $4 million of sales in the US alone in Q2, because despite good credit levels, a number of our providers just couldn't get the financing they want as tightened up with the rising interest rates. So that really explains that and of course, we're well served with the way we stratify our portfolio with Allegro as that entry price point and then Syndeo, we're able to cover the market well.

The next question comes from Olivia Tong with Raymond James. Please go ahead.

Great. Thanks. Good morning. I want to revisit gross margin again, because a couple of things that you said, obviously selling old refurbished systems, the Allegro, etcetera, which I imagine have lower gross margins relative to Syndeo. Was it always part of the plan to do that and are you continuing to sell old refurbished systems? And then, can you talk about the gross margin differential between some of the legacy systems and Syndeo because effectively, what it looks like is that you may be having a bit of a lower AUR relative to your prior expectations and with that, I'm kind of curious how you -- with the building blocks, you get to gross margin back to normal by beginning of next year? Thank you.

Olivia, thanks for your question. First of all, just to confirm, Allegro is not gross margin decretive. It's not diluted. It's in line with the margin. I think what the margin pressure we've faced has been more from the consumers, sorry, providers, purchasing the lower margin refurbished Syndeo. That's what drove the margin down. So, Allegro is a great margin. Of course, at $20,000, it's a lower price point, but perfect for that graduating estheticians and then provider, and then, obviously, the Syndeo for the provider wanting all the functionality which Brad talked to. And then, in terms of the gross margin, we will start to see, a sequential improvement of that in the second half of this year and being back by the middle of next year. we'll be over these short term headwinds. In essence, and I think we've talked about this before on previous calls, at this stage, we've planned on twofold. One, to have a lot more manufacturing in China, but at the moment, we've started that manufacturing. But as we've also been making, addressing the teething issues on the devices in the US, in essence, we've been having double costs of that US production and as well as China. So that's been a gross margin hit and moreover, we have, also had to postpone some of the value engineering projects, which we'll now address, because we've really focused the team on addressing the Syndeo issues in the US. We'll get over that during the end of Q3, and have line of sight back to gross margin of historical levels and more by the middle of next year.

The next question comes from Allen Gong with JPMorgan. Please go ahead.

Hi, Dean. Thanks for the question. I kind of want to touch up on guidance again. When I look at it, it does look a bit more 4Q loaded than I think we were originally expecting. 2Q came in a little bit stronger on the top line than we were expecting. And I know there's like definitely a little bit of moving pieces to the year, given the kind of the cadence of Syndeo launches internationally. So is there any more call you can provide just on, how you get confident in that really strong 4Q number? How we should think about, system sales progressing? How we should think about disposable sourcing?

Good morning, Alan. Thanks for the question, again, an important one. As I said, we maintain our conviction and our ability to hit our guidance. And I think we've talked before about we, from the start of the year, we said it would be about weighted. I think there's a few building blocks in there. Of course, China was locked down, really for us during much of Q2 and certainly Q4 of last year. You've seen how significant that is today on the call. That's, of course, bounced back strongly and continues to form well into Q3. And the same with EMEA in general and both of those markets have higher contribution margins than American business and, as our business mix continues to weigh more towards international, we expect to generate degrees of operating leverage throughout the P&L beyond the fixed-cost leverage you'd expect to see. So there's fixed-cost leverage. There's also the operating leverage, which is in terms of our investments. Our marketing and advertising is very front-weighted because of around the trade shows in our business. And we'll get leverage there in the second half, as well as the consumables. We've also got the international markets. When they launched Syndeo, they put through some price increases on the consumables. All of that flows through in the second half in Q4, which gives us line of sight to that step-up in EBITDA margin, which you see.

The next question comes from Linda Bolton-Weiser with D.A. Davidson. Please go ahead.

Yes, hi. Thank you. So your commentary about the small estheticians in the U.S. having trouble financing, it's a little bit of a different narrative about the positioning of your system, because I guess we were thinking of it as positioned as the trade-down, lower, more affordable system out there among estheticians. o it really changes the positioning and how we think about it. Maybe you could talk about, for the regular, bigger doctors and spas and whatnot who have a budget, who spend to that budget by the end of the year, causing you to have a bigger fourth quarter. It's sort of this issue seeping into that bigger provider as well and so you may see less demand from them, even though you've sort of positioned this as the affordable system, it seems like maybe this is a stretch. Can you just talk about how that affects, like, your fourth-quarter sales outlook?

Linda, thanks very much for the question. I'd say, with respect, I don't agree with your premise. I would say, first of all, the doctors and the medical channel and the growing medical spa channel, they consider even the Syndeo to be very cheap compared to the other boxes they sell from all the other brands you're very familiar with. I think, and for the esthetician just leaving, that's why we've always had the Allegro business there, as also the refurbishments of Syndeo, which makes them accessible. We see this as short-term headwinds. Pricing resistance from estheticians was never an issue until interest rates were so high, when you've got financing at 20%, of course, that is the short-term pain, which we'll get over. But fundamentally, you see, we still dropped, 30% more systems new globally in Q1, even in the US as well. Our systems sold during the quarter were up 25%. So, there's no real barrier to pricing and of course, we'll benefit, as you said, in Q4, particularly from doctors and the medical channel. Not only is that the biggest quarter of consumption for the year. But you're right, as they used to use up their capital expenditure quota to get their tax incentives, that's a key time for purchasing, not just in the US, but globally and with the rollout of Sendai and all the markets this year, they will be seizing the opportunity to buy that. So that's why we see and anticipate demand to continue to build throughout the year.

The next question comes from Bruce Jackson with The Benchmark Company. Please go ahead.

Hi, good morning, and thank you for taking my question. I'm going to take another run at the revenue guidance from a geographic standpoint. Can you give us a little bit of color on some of the regional dynamics? So how do you expect the US to unfold for the rest of this year and is Asia and are Asia and Europe going to remain strong? And then longer term, how do you see the regional mix changing with your sales in 2024?

Good morning, Bruce, and thanks for the question. This is a topic which we'll follow really closely. And I think as we look globally, despite the economic news headlines, globally, we see demand for hydrofacers remain resilient, as demonstrated by the accelerations in the consumable growth driven by volumes, which we've seen in all regions, as well as selling new systems and while no company is recession-proof, our upper middle class consumers are better able to weather recessionary pressures and prioritize self-care. So in terms of what we're seeing by region, in the US, demand remains healthy. You see that in the growth of the consumables, 29% during Q2, up a strong Q1. On systems, new systems we've sold grew 25%. That's on the non-trade-up ones in the US, which is even more than when we launched Syndeo last year. So in essence, we've been increasing our penetration and we see a very healthy market in the US. It's just where we've seen in terms on the device sales, not on the consumable sales. It's just some pressure on that SD because of the high interest rates, but that's why we've been able to not really lose business. We've been able to sell them refurbished Syndeo, or the Allegros. In terms of if we shift now to APAC, where we had a very strong quarter, of course, really the news there is the reacceleration in China and despite the negative news headlines from China, demand for HydraFacial remains very healthy. We see less seasonality in China than what you typically do in July and August in Europe or the US, same for Latin America and the Syndeo launch has been successful, and I think really underscores the enthusiasm in that market. Ultimately, in years to come, China will no doubt be our first market. The TAM there is two, three times bigger than that of the US and I think we're just getting started there with very, very low penetration, as you saw in the presentation. And of course, our positioning there as a cosmetic device, not a medical device, which is very different to our peer brands in the region, means that we have just a wider distribution and access to so many more providers and consumers in that key market. And then for EMEA, we've been extremely pleased with how EMEA has recovered since last year. Very successful launch of Syndeo in its early days in EMEA, but new systems growth in Q2 growing 64%. Consumer falls growing 28%, 29%. So very pleased with the growth of that EMEA and showing continued strength.

The next question comes from Kyle Rose with Canaccord Genuity. Please go ahead.

Hi, everyone. This is Kaitlin [ph] on for Kyle Rose. Just on the Allegro system, could you provide a little more color on kind of the distribution and how many systems are out in the market and the growth you're really seeing on those? And then just quickly on SkinStylus, you received the 510-K for the clearance of facial acne scarring recently. How are you thinking about launching this product on to your systems? Thank you.

Thank you. Thank you for the question. So the Allegro system -- the Allegro system has been around for many years. I would say it's a relatively small portion of our business, but has seen some growth recently, predominantly in the US from that first SD we've talked about, predominantly because of the high interest rates. And of course, we're very proud to be upgrading that, making some important changes, adding some technology so we can start collecting data like we do on Syndeo, and also adding the anti-twist lock counterfeit bottles like we have on Syndeo to really stamp out any of the sort of counterfeit solutions which we had seen in pockets in the US before. So very excited to see those changes on Allegro. It's got a similar margin to Syndeo, just a lower price point and then for skin stylists, of course, we're really excited for the new clearance we got from the FDA last week. We're now the only microneedling device approved for face and abdominal use. As I said earlier, the revenue this year, frankly, won't be material for the company, but it's already doing well. It's high margin, more accretive, actually, than the historic high levels of HydraFacial. So it adds a lot. I think later in the year, early next year, we'll give you more of a view on where we see the skin stylists' global revenues for the years to come, not just in the US, but globally as we get approval to sell it overseas.

This concludes our question-and-answer session. I would like to turn the conference back over to Andrew Stanleick, CEO, for any closing remarks.

Thank you, operator and thank you again to everyone for joining today's call. Our second quarter results demonstrate continued demand for HydraFacial and encouraging momentum across our most important growth markets. The organizational and operational changes we have implemented, paired with our ability to unlock operating leverage and an exciting innovation pipeline, position us to move forward with even greater confidence in executing against our FY 2023 and long-range financial targets. As I mentioned, we look forward to hosting Investor Day in the first half of 2024, and we will share more details in the coming months. Thank you, and have a wonderful day ahead.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.